Clinical Trial Update: G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating G1T38 (a CDK 4/6 inhibitor) in combination with fulvestrant for HR-positive, HER2-negative locally advanced or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasm
• Ductal Breast Carcinoma

Drugs mentioned

• Fulvestrant (fulvestrant)
• G1T38

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Carcinoma, Ductal, Breast, Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN